StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) stock analysis

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $281.77MP/E 5.0Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth2Performance6Health5Dividend0

Mixed13 of 30 checks passed

Elite Pharmaceuticals passes 13 of the 30 checks behind our score; 15 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
6/6
Financial health
5/6
Dividend
0/6

What stands out

  • Return on equity over 15%

    Return on equity was 74.3% over the last twelve months and averaged 30.8% over five years.

  • Return on capital over 10%

    Return on invested capital was 66.3%, above the 10% that usually covers the cost of capital.

  • No debt

    Elite Pharmaceuticals has no borrowings on its latest balance sheet.

  • Earnings grew over 5 years

    Net income grew 54.6% a year on average over the last five fiscal years.

What to watch

  • Gross margin slipping

    Gross margin was 43.5% over the last twelve months, against 55.8% a year earlier.

  • No dividend

    Elite Pharmaceuticals has not paid a dividend in the last twelve months.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth2/6

  • Revenue growing 10%+ a year

    Revenue grew 63.3% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 33.7% over the last twelve months; the Drugs median is 8.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin slipping

    Gross margin was 43.5% over the last twelve months, against 55.8% a year earlier.

Past performance6/6

  • Return on equity over 15%

    Return on equity was 74.3% over the last twelve months and averaged 30.8% over five years.

  • Return on capital over 10%

    Return on invested capital was 66.3%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Elite Pharmaceuticals's return on equity of 74.3% is above the Drugs median of -58.9%.

  • Earnings grew over 5 years

    Net income grew 54.6% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 40.2% over the last twelve months, against a 5-year average of 19.7%.

  • Net margin above the industry

    Elite Pharmaceuticals's net margin of 40.2% is above the Drugs median of -53.0%.

Financial health5/6

  • No debt

    Elite Pharmaceuticals has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    Operating income covers interest expense 318.4 times.

  • Short-term assets cover short-term debts

    Current assets are 3.76 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    Elite Pharmaceuticals has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Elite Pharmaceuticals. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 12.9
  • Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2012 to 2026

Gross margin

50.4%+3.6 pts over 5 years

Operating margin

33.0%+24.7 pts over 5 years

Net margin

30.1%+10.1 pts over 5 years

See a number that looks wrong?